::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::

CODEN : IAJPBB
issn 2349-7750

News Updates Latest Volumes: COSMOS IMPACT FACTOR (2018)- 4.153, GLOBAL IMPACT FACTOR(2014) - 0.384, (2015) - 0.437, Indo American Journal of Pharmaceutical Sciences,

ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

SURVIVAL RATE AND ASSESSMENT OF ACUTE MYELOID LEUKEMIA THROUGH PROGNOSTIC FACTORS

AUTHORS:

Moaz Ahmad, Hassan Bin Aziz, Hafiz Muhammad Tousif Afzal

ABSTRACT:

Background: Acute Myeloid Leukemia is malignant complication with important identified factors of prognosis. The objective of this research work was the development of the Prognosis’s assessment scheme in acute myeloid leukemia on the basis of prognostic factors. In few regions of world, like Pakistan or other countries, this particular scheme will be much beneficial specially when there is non-availability of cytogenetic testing. Methodology: In this research work, we analyzed 70 patients suffering from Acute Myeloid Leukemia during a period of five years in Mayo Hospital Lahore. We collected the data retrospectively from the medical history of the patients and analyzed this collected data with the help of Excel and Epi Info. Results: On the basis of age, Group A-1 (less than 40 years) had a survival of forty months, contrary to Group B-1 (≥ 40.0 years) with a nineteen months survival (P=0.00410). Group A-2 (patients with secondary Acute Myeloid Leukemia) survived for 15 months, whereas Group B-2 (patients with Acute Myeloid Leukemia de novo) survived for forty months (P=0.00210). In addition, Group A-3 (patients with mild co-morbidities) achieved a survival of forty months, Group B-3 (patients with moderate co-morbidities) survived for nineteen months, whereas Group C-3 (patients with severe comorbidities) survived for seven months (P=0.00370). According to blast number and WBC, Group A-4 (higher levels) had a survival of twenty-five months, whereas Group B-4 (lower levels) survived for forty months (P=0.00350). Conclusion: The studied prognostic factors are much useful to detect the level of risk of the Acute Myeloid Leukemia for every patient at the time of diagnosis. We formulated this assessment prognosis scheme with 3 risk groups on the basis of secondary Acute Myeloid Leukemia, age, co-morbidity, blasts, WBC & cytogenetic examination. Keywords: Prognosis, Factor, Acute Myeloid Leukemia, Survival, Co-Morbidity, Excel.